Page 2030 — спільне прийняття рішення про скринінг раку легені. A structured, low-dose CT screening counseling visit walking through the required discussion elements for eligible high-risk patients.
The shared decision-making visit opens with the single most important number a patient needs: how much does annual low-dose CT (LDCT) screening actually change the odds of dying from lung cancer? The answer comes from two landmark randomized controlled trials — the U.S. National Lung Screening Trial (NLST) and the Dutch-Belgian NELSON trial — both of which found a meaningful, statistically significant relative reduction in lung cancer mortality among high-risk current and former smokers screened with LDCT compared with the control arm.
A screening test can find more cancers without ever saving a single additional life — lead-time bias (diagnosing earlier without changing the moment of death) and length-time bias (preferentially catching slow-growing tumors) can both inflate apparent benefit. This is why NLST and NELSON were designed as randomized trials measuring lung-cancer-specific mortality as the primary endpoint, not simply detection rate or five-year survival.
NLST (2011, New England Journal of Medicine) randomized over 53,000 high-risk participants to three annual rounds of LDCT versus chest radiograph. The trial was stopped early because the LDCT arm showed a 20% relative reduction in lung cancer mortality — the first screening test ever shown to reduce lung cancer deaths in a randomized trial.
NELSON (2020, NEJM) randomized over 15,000 participants to LDCT at increasing intervals versus no screening, using a volumetric nodule-management protocol. At 10 years, lung cancer mortality was reduced by roughly 24% in men and an even larger relative reduction in the smaller cohort of women, reinforcing and extending the NLST findings in a different healthcare system and screening protocol.
Both trials targeted a specific high-risk population — heavy smoking history, defined age range — because the absolute benefit of screening depends heavily on baseline risk. The mortality reduction is a relative measure; explaining the corresponding absolute risk reduction and number-needed-to-screen helps patients understand what the percentage actually means for someone like them.
Effective mortality-benefit counseling avoids reciting a bare percentage and instead anchors it to the patient’s own risk profile:
• Start from personal risk: pack-years, age, and years since quitting all shift a patient’s baseline probability of developing lung cancer — and therefore how much absolute benefit screening can offer. • Use plain framing: "for people with a smoking history like yours, screening for several years has been shown, in large studies, to lower the chance of dying specifically from lung cancer by roughly one-fifth to one-quarter, compared with not screening." • Acknowledge what the trials do not show: neither trial proves benefit outside the studied age/pack-year eligibility window, and benefit accrues only with sustained annual adherence, not a single scan. • Connect benefit to the rest of the visit: the mortality benefit is the reason screening is offered at all, but it must be weighed against the harms discussed in the following stages — false positives, overdiagnosis, cumulative radiation, and incidental findings.
This is often the hardest part of the conversation, because it runs against intuition. Patients generally assume that finding something is unambiguously good. In lung cancer screening, a large share of "positive" scans turn out not to be cancer at all (false positives), and a smaller but real fraction of cancers that are found and treated would never have caused symptoms or death in the patient’s lifetime (overdiagnosis) — yet the patient still undergoes the anxiety, imaging, and sometimes invasive follow-up of a cancer diagnosis and treatment.
A "positive" LDCT result typically means a pulmonary nodule was detected that meets size or growth criteria for further workup — not that cancer has been diagnosed. In NLST, roughly a quarter of participants had at least one positive screening round, yet the overwhelming majority of those nodules were ultimately benign: scarring, infection, inflammation, or simply small nodules that never grow.
Modern nodule-management protocols (e.g., Lung-RADS) have reduced false-positive rates substantially compared with the original NLST protocol by using structured size and growth thresholds and risk-stratified follow-up intervals rather than referring every visible nodule for immediate biopsy. Most positive findings are managed with short-interval repeat CT rather than invasive procedures.
Still, even a "manage with repeat CT in 3–6 months" result produces real harm: anxiety while awaiting the next scan, additional radiation exposure, and occasionally an unnecessary invasive procedure (needle biopsy, bronchoscopy, or even surgery) for what proves to be a benign nodule.
Overdiagnosis is a distinct and more difficult concept: it means detecting a true, histologically confirmed lung cancer that was growing so slowly — or was so biologically indolent — that it would never have produced symptoms or caused death during the patient’s remaining lifetime, had it never been found. Because clinicians cannot know in advance which screen-detected cancer is overdiagnosed, essentially all are treated, which means some patients undergo surgery, chemotherapy, or radiation for a cancer that carried no true threat to them.
Estimates of the overdiagnosis rate in NLST-detected cancers have ranged from roughly one in ten to considerably higher in some modeling analyses, particularly for certain slow-growing subtypes (e.g., some adenocarcinoma-in-situ or minimally invasive lesions). This is one of the most actively studied and debated numbers in the screening literature, and honest counseling acknowledges the uncertainty rather than presenting a single precise figure as settled fact.
The practical implication for the patient: choosing to screen means accepting that some fraction of any future "positive" result will lead down a path of treatment for a cancer that might never have needed it — a trade-off that is easier to accept once named explicitly than when discovered only after the fact.
Naming overdiagnosis before a scan is ever performed — not after an abnormal result — is what separates genuine informed shared decision-making from simple consent-taking. Patients who understand this concept up front tend to experience less distress when a positive result turns out to require watchful waiting rather than an alarming diagnosis.
Because lung cancer screening is intended as an annual, multi-year program rather than a one-time test, the radiation conversation is inherently about accumulation over time, not a single exposure. Low-dose CT protocols were specifically engineered to minimize the radiation dose per scan relative to a standard diagnostic chest CT, but the benefit of screening depends on returning year after year — so the counseling has to be honest about the cumulative dose across a realistic multi-year screening course.
Low-dose CT protocols use reduced tube current (mA) and optimized reconstruction algorithms to produce images adequate for nodule detection while delivering only a fraction of the radiation of a standard diagnostic chest CT. A typical LDCT scan delivers on the order of 1–1.5 millisieverts (mSv), compared with roughly 7–8 mSv for a full-dose diagnostic chest CT — for context, a routine two-view chest X-ray delivers a small fraction of even the LDCT dose, but chest X-ray was shown in NLST to be substantially inferior at detecting early lung cancer.
The dose reduction is possible because screening is looking for something specific — nodules against the relatively high-contrast background of aerated lung — rather than needing the fine soft-tissue detail required to characterize a known abnormality diagnostically. This tradeoff (lower image quality, adequate for its narrow purpose) is what makes annual screening radiologically sustainable.
A patient who screens annually for a decade accumulates roughly 10–15 mSv from the LDCT scans alone, before accounting for any additional diagnostic imaging triggered by a positive result (a follow-up diagnostic CT for a suspicious nodule delivers a materially higher dose than the LDCT itself). Modeling studies that estimate the radiation-induced cancer risk from a realistic multi-year LDCT screening course consistently find that risk to be small relative to the mortality benefit demonstrated in the eligible high-risk population — this is precisely why organizations recommend screening only within the defined age and smoking-history eligibility window, where the balance favors screening, rather than in lower-risk populations where it likely would not.
Honest counseling on this point includes three components: (1) each individual scan is low-dose by design, (2) the relevant number for a returning patient is the cumulative dose over the planned multi-year course, not the single-scan number, and (3) regulatory and specialty-society guidance already restricts eligibility specifically to the population in whom modeling shows the mortality benefit outweighs the cumulative radiation and other harms.
A patient who asks "isn’t getting a CT every year for cancer screening going to give me cancer?" deserves a direct answer: the modeled radiation-attributable risk from a realistic screening course is small and is already factored into why eligibility is restricted to the higher-risk group in whom the mortality benefit clearly outweighs it — the conversation should say this plainly rather than deflect.
A chest CT, even a low-dose screening protocol, images far more anatomy than the lungs alone — coronary arteries, the thyroid, the adrenal glands, the upper abdomen, and the bones of the chest all appear on the same images. Incidental findings unrelated to lung cancer are common, and preparing the patient for this possibility before the first scan prevents a confusing or frightening surprise later and sets realistic expectations about what additional follow-up may or may not be needed.
Because the LDCT field of view captures the entire chest and part of the upper abdomen, radiologists routinely encounter findings unrelated to the pulmonary nodules screening is designed to detect:
• Coronary artery calcification — often reported qualitatively (present/absent, mild/moderate/severe) and can prompt a conversation about cardiovascular risk reduction, an incidental benefit of screening in current and former smokers who already carry elevated cardiovascular risk. • Emphysema and other structural lung findings — visible even without a discrete nodule, sometimes the first objective evidence of COPD in a patient who has not been formally diagnosed. • Thyroid nodules, adrenal nodules, hepatic or renal lesions, and bone findings at the margins of the scan field — usually benign but occasionally warranting a targeted follow-up study. • Aortic aneurysm or other vascular findings — uncommon but clinically significant when present.
The great majority of incidental findings are simply noted in the report without requiring any action; only a minority trigger a recommendation for additional imaging or referral.
Patients who are told in advance that "this scan looks at your whole chest, not just for cancer, so the report may mention other things we notice — most of which are minor and expected, and we’ll go over anything that needs a closer look" tend to respond to an incidental finding with far less alarm than patients hearing about it for the first time in a phone call after the scan.
Setting this expectation up front accomplishes several things: it normalizes the likely appearance of incidental notes in the report, it distinguishes findings that are simply documented from findings that require action, and it reassures the patient that the screening program includes a plan for following up anything clinically meaningful — rather than leaving the patient to wonder whether an unfamiliar term in their report was overlooked.
Documenting that this discussion occurred is also one of the required elements of a billable, guideline-concordant shared decision-making visit — not simply good bedside practice, but a program requirement tied to coverage for the screening itself.
The visit concludes by bringing every prior discussion element together into a documented shared decision — a record that mortality benefit, false-positive/overdiagnosis risk, cumulative radiation exposure, and incidental finding possibility were all discussed, and that the patient, now informed, has decided whether to proceed. For patients who currently smoke, the same visit integrates smoking cessation counseling and, where relevant, referral to cessation resources — both because it is required for program compliance and because it may offer more benefit than the screening itself.
A guideline-concordant shared decision-making visit is expected to produce a record showing that each required element was actually discussed, not merely that a visit occurred. In practice that means documenting:
1. Confirmation of eligibility — age, pack-year history, and current smoking status or years since quitting. 2. That mortality-benefit evidence was discussed in terms the patient could apply to their own risk. 3. That false-positive rates and the concept of overdiagnosis were explained, including that most positive results are not cancer. 4. That cumulative radiation exposure from a multi-year annual screening course was discussed in the context of its favorable risk-benefit balance for this population. 5. That the possibility of incidental findings unrelated to lung cancer was raised in advance. 6. The patient’s expressed decision — to proceed with screening or not — reflecting their own values and preferences, not a default assumption. 7. For current smokers, that cessation counseling was delivered or offered as part of the same visit.
Use of a formal decision aid (a structured handout, video, or decision-support tool covering these same elements) is commonly recommended to support consistency and comprehension, and its use is often itself documented as part of the visit.
The documentation exists to certify that genuine informed shared decision-making happened — the paperwork is a byproduct of the conversation, not a substitute for it. A visit that checks every box without the patient actually understanding the trade-offs has satisfied the letter of the requirement while failing its purpose.
Every patient eligible for lung cancer screening by definition has a substantial smoking history, and a large share are still current smokers at the time of the visit. Smoking cessation counseling is folded into the same encounter for two converging reasons.
First, it is a program and coverage requirement: guideline-concordant screening visits are expected to include cessation counseling for current smokers, tying reimbursement to genuine engagement with the modifiable risk factor that dominates lung cancer risk in this population.
Second, and more fundamentally, quitting smoking reduces a current smoker’s future lung cancer risk, cardiovascular risk, and overall mortality risk by a larger margin than screening itself can offer — screening finds cancer earlier, but cessation reduces the chance of developing it, and of dying from the many other smoking-related conditions screening does not address at all. Framing screening and cessation as complementary, not competing, priorities — "screening is not a substitute for quitting, it is what we do while you’re working on quitting, and after" — closes the loop on a visit whose real goal was never simply to schedule a scan, but to leave the patient genuinely better informed and better supported.